Lymphovascular Invasion Is Associated with Mutational Burden and PD-L1 in Resected Lung Cancer.
High tumor mutational burden (TMB) and PD-L1 expression are leading biomarkers in metastatic non-small cell lung cancer (NSCLC) and predict favorable response to checkpoint inhibitors. We sought to identify clinicopathologic characteristics associated with elevated TMB and PD-L1 expression among patients who underwent resection for NSCLC. NSCLC patients undergoing primary resection (2016-2018) were prospectively enrolled in an immunogenomic profiling project (ICON). Multiplex immunofluorescence (mIF) quantified densities (cells/mm2) of CD3+, CD3+CD8+, CD3+CD8+PD-1+, malignant cells (MCs), MCsPD-L1+, CD68+, CD68+PD-L1+, and CD20+ cells. Whole exome sequencing quantified TMB (mutations/megabase). TMB and MCsPD-L1+ were dichotomized according to the median of each. 55 patients completed mIF and WES profiling. 41.8% (23/55) had pathologic stage I disease. Median TMB and MCsPD-L1+ were 3.91 and 0.62 cells/mm2, respectively. TMB was higher among smokers (p=0.001) and tumors with lymphovascular invasion (LVI)(p=0.051). TMB was positively correlated with densities of MCsPD-L1+ (r=0.293,p=0.030), CD68+PD-L1+ (r=0.289, p=0.033), and CD20+ (r=0.310,p=0.043) cells. The density of MCsPD-L1+ was associated with increased CD3+CD8+ (r=0.319,p=0.018) and CD68+PD-L1+ (r=0.371,p=0.005) cells. Patients with PD-L1HighTMBHigh tumors (30.9%, 17/55) had higher intratumoral densities of CD3+, CD3+CD8+, CD68+, CD68+PD-L1+, and CD20+ cells. On multivariable analysis LVI was associated with synchronous elevated TMB and PD-L1 expression (OR 3.53,p=0.039). NSCLC tumors with elevated TMB and PD-L1 expression are associated with LVI and increased intratumoral immune cell infiltration. These findings may potentially improve patient selection for checkpoint inhibitor therapy trials in the adjuvant setting.